Fulgent Genetics Soars 10.59% on Q2 Revenue Growth

Fulgent Genetics' stock surged 10.59% in pre-market trading on August 1, 2025, reflecting a significant boost in investor confidence.

Fulgent Genetics reported its second-quarter 2025 financial results, showcasing a total revenue of $81.8 million. Core revenue grew by 16% year-over-year, reaching $81.7 million. Despite these positive figures, the company reported a GAAP loss, indicating ongoing challenges in achieving profitability.

The company's strategic shift towards precision medicine is a key focus, with significant investments in research and development. Fulgent Genetics faces $25 million in R&D costs and a projected non-GAAP loss of $0.65 for 2025. However, the company holds $814.6 million in cash, providing a 3-4 year runway for continued development and innovation.

Fulgent Genetics' revenue growth of 13.90% reflects its ability to expand in a challenging market environment. The company's financial health is further supported by a recent revenue growth rate of 13.92%, demonstrating its capacity to generate substantial revenue despite market challenges.